Details of the Drug

General Information of Drug (ID: DMACYW6)

Drug Name

NKTR-214

Synonyms

bempegaldesleukin

Indication

Disease Entry	ICD 11	Status	REF
Melanoma	2C30	Phase 3	[1]
------------------------------------------------------------------------------------

Drug Type

Recombinant protein

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin 2 receptor beta (IL2RB)	TT9721Y	IL2RB_HUMAN	Agonist	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Melanoma

ICD Disease Classification

2C30

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Interleukin 2 receptor beta (IL2RB)	DTT	IL2RB	7.52E-01	-0.06	-1.11
Interleukin 2 receptor beta (IL2RB)	DTT	IL2RB	1.96E-01	-4.70E-03	-0.01

Molecular Expression Atlas (MEA)

Jump to Detail Molecular Expression Atlas of This Drug

References

1	ClinicalTrials.gov (NCT03635983) A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma. U.S. National Institutes of Health.
2	Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy. Nat Commun. 2020 Jan 31;11(1):661.